Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Mount Sinai, Boehringer Ingelheim to Evaluate Nintedanib for Fibrosing ILD Following COVID-19

americanpharmaceuticalreviewDecember 07, 2020

Tag: Mount Sinai , Boehringer Ingelheim , COVID-19 , nintedanib , Fibrosing ILD

PharmaSources Customer Service